Literature DB >> 3636157

Effects of mevinolin in rat liver: evidence for a lack of coupling between synthesis of hydroxymethylglutaryl-CoA reductase and cholesterol 7 alpha-hydroxylase activity.

I Björkhem.   

Abstract

The effect of treatment of rats with the hydroxymethylglutaryl-CoA reductase inhibitor, mevinolin, on 7 alpha-hydroxylation of cholesterol was studied. Treatment with 0.1% mevinolin in diet for 3 days was found to have an inhibitory effect on 7 alpha-hydroxylation of cholesterol (about 35%). Treatment with cholestyramine increased 7 alpha-hydroxylation of both exogenously added and endogenous microsomal cholesterol 3-4-fold. Combined treatment with both cholestyramine and mevinolin decreased this stimulation to 2-2.5-fold. Treatment with 2% cholesterol in diet increased 7 alpha-hydroxylation of exogenous cholesterol about 2-fold and 7 alpha-hydroxylation of endogenous cholesterol about 3.5-fold. The stimulatory effect of cholesterol was reduced or abolished when 0.1% mevinolin was added to the cholesterol-containing diet. With the exception of the experiments with cholesterol in the diet, all experiments including mevinolin gave a marked stimulation (up to 60-fold) of the hydroxymethylglutaryl-CoA reductase activity under the in vitro conditions employed. The concentration of free cholesterol in the liver microsomes was not significantly changed in any of these experiments. It is concluded that there is no coupling between induction of synthesis of hydroxymethylglutaryl-CoA reductase protein and cholesterol 7 alpha-hydroxylase activity. The inhibitory effect of mevinolin on cholesterol 7 alpha-hydroxylase activity under experimental conditions where most of the effect of mevinolin on hydroxymethylglutaryl-CoA reductase was abolished by treatment with cholesterol suggest that the effect of mevinolin on the cholesterol 7 alpha-hydroxylase may be independent of its effect on cholesterol synthesis. The over-all results do not favour the hypothesis that cholesterol synthesis and cholesterol availability are the most important determinants for the regulation of the cholesterol 7 alpha-hydroxylase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3636157     DOI: 10.1016/0005-2760(86)90116-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.

Authors:  T Yoshida; A Honda; J Shoda; M Abei; Y Matsuzaki; N Tanaka; H Miyazaki; T Osuga
Journal:  Lipids       Date:  1997-08       Impact factor: 1.880

2.  Inhibition of cholesterol synthesis by lovastatin tested on six human cell types in vitro.

Authors:  D D Sviridov; I G Safonova; M Y Pavlov; V A Kosykh; E A Podrez; A S Antonov; I V Fuki; V S Repin
Journal:  Lipids       Date:  1990-03       Impact factor: 1.880

3.  Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.

Authors:  S Okamoto; K Nakano; K Kosahara; M Kishinaka; H Oda; H Ichimiya; K Chijiiwa; S Kuroki
Journal:  J Gastroenterol       Date:  1994-02       Impact factor: 7.527

4.  Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture.

Authors:  T Clerc; V Sbarra; N Domingo; J P Rault; N Diaconescu; V Moutardier; N Hasselot; H Lafont; G Jadot; C Laruelle; F Chanussot
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  Effects of perturbations in hepatic free and esterified cholesterol pools on bile acid synthesis, cholesterol 7 alpha-hydroxylase, HMG-CoA reductase, acyl-CoA:cholesterol acyltransferase and cytosolic cholesteryl ester hydrolase.

Authors:  W M Grogan; M L Bailey; D M Heuman; Z R Vlahcevic
Journal:  Lipids       Date:  1991-11       Impact factor: 1.880

6.  Effect of crilvastatin, a new cholesterol lowering agent, on unesterified LDL-cholesterol metabolism into bile salts by rat isolated hepatocytes.

Authors:  T Clerc; V Sbarra; N Diaconescu; H Lafont; G Jadot; C Laruelle; F Chanussot
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.